|
|
Volumn 272, Issue 5270, 1996, Pages 1882-1883
|
|
Protease inhibitors: A tale of two companies
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIVIRUS AGENT;
CD4 ANTIGEN;
HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;
INDINAVIR;
L 689502;
LAMIVUDINE;
NELFINAVIR;
PLACEBO;
PROTEINASE INHIBITOR;
RENIN INHIBITOR;
RITONAVIR;
RNA DIRECTED DNA POLYMERASE;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
SAQUINAVIR;
UNCLASSIFIED DRUG;
VIRUS PROTEIN;
ZIDOVUDINE;
CLINICAL TRIAL;
DOG;
DRUG COST;
DRUG MANUFACTURE;
DRUG MECHANISM;
DRUG MIXTURE;
DRUG RESEARCH;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
NAUSEA;
NEPHROLITHIASIS;
NONHUMAN;
NOTE;
PRIORITY JOURNAL;
VIRUS REPLICATION;
ACQUIRED IMMUNODEFICIENCY SYNDROME;
ANIMALS;
ANTIVIRAL AGENTS;
CHEMISTRY, PHARMACEUTICAL;
CONTROLLED CLINICAL TRIALS;
DRUG APPROVAL;
DRUG DESIGN;
DRUG INDUSTRY;
HIV;
HIV PROTEASE INHIBITORS;
HUMANS;
INDINAVIR;
PYRIDINES;
RITONAVIR;
THIAZOLES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
VALINE;
CANIS FAMILIARIS;
HUMAN IMMUNODEFICIENCY VIRUS;
|
|
EID: 0030017661
PISSN: 00368075
EISSN: None
Source Type: Journal
DOI: 10.1126/science.272.5270.1882 Document Type: Note |
|
Times cited : (22)
|
|
References (0)
|